Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Yixintang Pharmaceutical Group Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Yixintang Pharmaceutical Group kazanç ve gelirin sırasıyla yıllık 31.5% ve 12.7% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 32.2% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 11.6% olacağı tahmin edilmektedir.

Anahtar bilgiler

31.5%

Kazanç büyüme oranı

32.2%

EPS büyüme oranı

Consumer Retailing kazanç büyümesi	39.0%
Gelir büyüme oranı	12.7%
Gelecekteki özkaynak getirisi	11.6%
Analist kapsamı	Good
Son güncelleme	18 Sep 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Market Cool On Yixintang Pharmaceutical Group Co., Ltd.'s (SZSE:002727) Earnings

Sep 25

These 4 Measures Indicate That Yixintang Pharmaceutical Group (SZSE:002727) Is Using Debt Reasonably Well

Jul 15

Some Investors May Be Worried About Yixintang Pharmaceutical Group's (SZSE:002727) Returns On Capital

Jun 29

Yixintang Pharmaceutical Group Co., Ltd.'s (SZSE:002727) Intrinsic Value Is Potentially 26% Below Its Share Price

Jun 13

Market Cool On Yixintang Pharmaceutical Group Co., Ltd.'s (SZSE:002727) Earnings Pushing Shares 27% Lower

Jun 13

Yixintang Pharmaceutical Group (SZSE:002727) Is Due To Pay A Dividend Of CN¥0.40

May 27

Yixintang Pharmaceutical Group's (SZSE:002727) Conservative Accounting Might Explain Soft Earnings

May 03

Investors Holding Back On Yixintang Pharmaceutical Group Co., Ltd. (SZSE:002727)

Apr 15

Return Trends At Yixintang Pharmaceutical Group (SZSE:002727) Aren't Appealing

Mar 06

Kazanç ve Gelir Büyüme Tahminleri

SZSE:002727 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CNY Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	25,059	1,005	2,039	1,930	10
12/31/2025	21,992	860	1,940	1,958	10
12/31/2024	18,871	621	1,512	1,753	7
6/30/2024	18,010	327	2,086	2,355	N/A
3/31/2024	18,044	552	1,985	2,269	N/A
12/31/2023	17,380	549	1,862	2,115	N/A
9/30/2023	18,219	1,019	1,971	2,361	N/A
6/30/2023	18,142	1,096	2,234	2,553	N/A
3/31/2023	17,872	1,070	2,402	2,733	N/A
1/1/2023	17,432	1,010	2,148	2,497	N/A
9/30/2022	16,115	835	2,125	2,509	N/A
6/30/2022	15,851	816	1,537	1,947	N/A
3/31/2022	15,154	840	1,295	1,668	N/A
1/1/2022	14,587	922	1,400	1,792	N/A
9/30/2021	13,916	950	815	1,120	N/A
6/30/2021	13,329	897	610	928	N/A
3/31/2021	12,998	846	690	988	N/A
12/31/2020	12,656	790	753	1,033	N/A
9/30/2020	12,056	724	827	1,023	N/A
6/30/2020	11,448	683	1,077	1,257	N/A
3/31/2020	10,978	633	984	1,185	N/A
12/31/2019	10,479	604	776	983	N/A
9/30/2019	10,219	587	838	1,017	N/A
6/30/2019	9,945	566	719	892	N/A
3/31/2019	9,585	565	828	988	N/A
1/1/2019	9,176	521	480	636	N/A
9/30/2018	8,768	525	481	619	N/A
6/30/2018	8,391	499	442	579	N/A
3/31/2018	8,116	457	N/A	330	N/A
12/31/2017	7,751	423	N/A	391	N/A
9/30/2017	7,316	386	N/A	166	N/A
6/30/2017	6,949	373	N/A	44	N/A
3/31/2017	6,584	345	N/A	134	N/A
12/31/2016	6,249	353	N/A	193	N/A
9/30/2016	5,971	379	N/A	124	N/A
6/30/2016	5,774	369	N/A	220	N/A
3/31/2016	5,600	361	N/A	163	N/A
12/31/2015	5,321	346	N/A	187	N/A
9/30/2015	5,080	323	N/A	234	N/A
6/30/2015	4,854	314	N/A	58	N/A
3/31/2015	4,589	310	N/A	34	N/A
12/31/2014	4,428	297	N/A	176	N/A
9/30/2014	4,236	292	N/A	211	N/A
6/30/2014	3,995	279	N/A	228	N/A
3/31/2014	3,792	253	N/A	284	N/A
12/31/2013	3,547	241	N/A	228	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 002727 'nin tahmini kazanç büyümesi (yıllık 31.5% ) tasarruf oranının ( 2.9% ) üzerindedir.

Kazançlar ve Piyasa: 002727 şirketinin kazançlarının (yıllık 31.5% ) CN pazarından (yıllık 23.2% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: 002727 şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.

Gelir ve Pazar: 002727 şirketinin gelirinin (yıllık 12.7% ) CN pazarından (yıllık 13.2% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 002727 şirketinin gelirinin (yıllık 12.7% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 002727 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 11.6 %).

Yixintang Pharmaceutical Group Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus EPS estimates fall by 32%

Price target decreased by 10% to CN¥20.81

Consensus revenue estimates decrease by 11%

Price target decreased by 8.1% to CN¥35.37

Price target increased to CN¥38.51

Price target decreased to CN¥33.64

Recent updates

Yixintang Pharmaceutical Group Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Investor sentiment improves as stock rises 18%

Market Cool On Yixintang Pharmaceutical Group Co., Ltd.'s (SZSE:002727) Earnings

Consensus EPS estimates fall by 32%

Price target decreased by 10% to CN¥20.81

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Yixintang Pharmaceutical Group Co., Ltd. (SZSE:002727) commences an Equity Buyback Plan for CNY 150 million worth of its shares, under the authorization approved on July 2, 2024.

Yixintang Pharmaceutical Group Co., Ltd. (SZSE:002727) commences an Equity Buyback Plan for CNY 150 million worth of its shares, under the authorization approved on July 2, 2024.

These 4 Measures Indicate That Yixintang Pharmaceutical Group (SZSE:002727) Is Using Debt Reasonably Well

Now 20% overvalued

Yixintang Pharmaceutical Group Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Some Investors May Be Worried About Yixintang Pharmaceutical Group's (SZSE:002727) Returns On Capital

Yixintang Pharmaceutical Group Co., Ltd.'s (SZSE:002727) Intrinsic Value Is Potentially 26% Below Its Share Price

Market Cool On Yixintang Pharmaceutical Group Co., Ltd.'s (SZSE:002727) Earnings Pushing Shares 27% Lower

Yixintang Pharmaceutical Group (SZSE:002727) Is Due To Pay A Dividend Of CN¥0.40

Dividend of CN¥0.40 announced

Yixintang Pharmaceutical Group Co., Ltd. Announces Dividend Implementation for 2023, Payable on 30 May 2024

Yixintang Pharmaceutical Group's (SZSE:002727) Conservative Accounting Might Explain Soft Earnings

Yixintang Pharmaceutical Group Co., Ltd., Annual General Meeting, May 21, 2024

Yixintang Pharmaceutical Group Co., Ltd., Annual General Meeting, May 21, 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Investors Holding Back On Yixintang Pharmaceutical Group Co., Ltd. (SZSE:002727)

Yixintang Pharmaceutical Group Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Full year 2023 earnings released: EPS: CN¥0.92 (vs CN¥1.70 in FY 2022)

Return Trends At Yixintang Pharmaceutical Group (SZSE:002727) Aren't Appealing

Now 21% undervalued after recent price drop

Yixintang Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024

Consensus revenue estimates decrease by 11%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Second quarter 2023 earnings released: EPS: CN¥0.45 (vs CN¥0.40 in 2Q 2022)

Price target decreased by 8.1% to CN¥35.37

Yixintang Pharmaceutical Group Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 26 May 2023

Yixintang Pharmaceutical Group Co., Ltd. Approves Cash Dividend for the Year 2022

Full year 2022 earnings released: EPS: CN¥1.70 (vs CN¥1.56 in FY 2021)

Price target increased to CN¥38.51

Investor sentiment improved over the past week

Insufficient new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improved over the past week

Price target decreased to CN¥33.64

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Price target decreased to CN¥40.40

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to CN¥46.85

High number of new directors

Yixintang Pharmaceutical Group Co., Ltd. Proposes Cash Dividend on A Shares for the Year 2021, Payable on April 29, 2022

Yixintang Pharmaceutical Group Co., Ltd. Approves Profit Distribution

Yixintang Pharmaceutical Group Co., Ltd., Annual General Meeting, Apr 20, 2022

Price target decreased to CN¥46.85

Yixintang Pharmaceutical Group Co., Ltd. Proposes Final Cash Dividend for the Year 2021

Full year 2021 earnings: EPS and revenues miss analyst expectations

Now 22% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.41 (vs CN¥0.33 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.45 (vs CN¥0.37 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.44 (vs CN¥0.36 in 1Q 2020)

Price target increased to CN¥50.86

Investor sentiment improved over the past week

Yixintang Pharmaceutical Group Co., Ltd. Proposes Final Cash Dividend for the Year 2020

Full year 2020 earnings released: EPS CN¥1.38 (vs CN¥1.06 in FY 2019)

Revenue and earnings beat expectations

Full year 2020 earnings released: EPS CN¥1.38 (vs CN¥1.06 in FY 2019)

New 90-day high: CN¥45.79

Yixintang Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2020 Results on Mar 16, 2021

New 90-day low: CN¥34.00

Investor sentiment deteriorated over the past week

New 90-day high: CN¥42.23